Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma

Oncogenic activated RAS mutations have been detected in 50% of de novo and 70% of relapsed multiple myeloma (MM) patients. Translocation t(11;14) involving IgH/CCDN1 and overexpression of cyclin-Ds are early events in MM pathogenesis, enhancing uncontrolled MM cell growth. We hypothesized that targe...

Full description

Bibliographic Details
Main Authors: Abiatari, I. (Author), Adamia, S. (Author), Anderson, K.C (Author), Bhatt, S. (Author), Chyra, Z. (Author), Dorfman, D.M (Author), Fell, G.G (Author), Hideshima, T. (Author), Letai, A. (Author), Pioso, M.S (Author), Tai, Y.-T (Author), Wen, K. (Author)
Format: Article
Language:English
Published: Springer Nature 2022
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items